简介：The FUNDAMENTAL Study specifically targeted difficult-to-treat patients in an attempt to improve SVR rates in patients chronically infected with HCV. What they found was that alisporivir (ALV) drastically improved responses when compared with peg-interferon/ribavirin (IFN/RBV) alone.